Where Might Inovio Shares Land Post-Breakout? (INO)

Share it with your friends Like

Thanks! Share it with your friends!


Where Might Inovio Shares Land Post-Breakout? (INO)
Investors had been growing impatient with the company after a pivotal Phase III study of VGX-3100 for cervical dysplasia was delayed by the Food & Drug Administration, while
the Trump Administration’s plans to defund public health initiatives could have an adverse impact on its Ebola, Zika, and MERS-related products that rely on such funding.
The response rate are also consistent with data from its Ebola, Zika,
and MERS clinical trials in terms of demonstrating a 100% vaccine response with a very favorable safety profile.
The favorable clinical data supports the company’s longer bullish case,
but long-term investors must still contend with uncertainty in the VGX-3100 program and the potential need for additional capital before commercializing its major programs.
From a technical standpoint, the stock broke out from its upper trend line resistance
and 200-day moving average at around $7.38 to about $12.00 before falling to prior highs at around $8.50.
Inovio Pharmaceuticals Inc. (INO) soared more than 20% after reporting a nearly 100% immune response rate in its HIV vaccine candidate PENNVAX®-GP.


Write a comment